Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SymBio Pharmaceuticals's Enterprise Value for the quarter that ended in Jun. 2026 was 円5,123 Mil.
SymBio Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was 円-5,945 Mil. SymBio Pharmaceuticals's Earnings Yield (Joel Greenblatt) for the quarter that ended in Jun. 2026 was -116.28%.
The historical rank and industry rank for SymBio Pharmaceuticals's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
TSE:4582'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1741.76 Med: -38.39 Max: 2092.44
Current: -135.14
During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of SymBio Pharmaceuticals was 2092.44%. The lowest was -1741.76%. And the median was -38.39%.
TSE:4582's Earnings Yield (Joel Greenblatt) % is ranked worse than 98.61% of 1010
companies
in the Drug Manufacturers industry
Industry Median: 2.965
vs TSE:4582: -135.14
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. SymBio Pharmaceuticals's Forward Rate of Return (Yacktman) % for the quarter that ended in Jun. 2026 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
SymBio Pharmaceuticals Earnings Yield (Joel Greenblatt) % Related Terms
SymBio Pharmaceuticals Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for SymBio Pharmaceuticals's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4582 vs ZTS: Earnings Yield (Joel Greenblatt) % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, SymBio Pharmaceuticals's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SymBio Pharmaceuticals Earnings Yield (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, SymBio Pharmaceuticals's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where SymBio Pharmaceuticals's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
SymBio Pharmaceuticalss Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2025 is calculated as
SymBio Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-5,945 Mil.
What does a Earnings Yield (Joel Greenblatt) % of -116.28% mean?
SymBio Pharmaceuticals (TSE:4582) has a Earnings Yield (Joel Greenblatt) % of -116.28% as of Jun. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on SymBio Pharmaceuticals and its competitors. According to the industry distribution chart, SymBio Pharmaceuticals ranks #996 out of 1010 companies in the Drug Manufacturers industry, placing it in the top 98.6%.
Is SymBio Pharmaceuticals' Earnings Yield (Joel Greenblatt) % too high?
SymBio Pharmaceuticals' current Earnings Yield (Joel Greenblatt) % is -116.28%. Based on the distribution chart, SymBio Pharmaceuticals ranks #996 out of 1010 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, SymBio Pharmaceuticals has a GF Score™ of 36/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does SymBio Pharmaceuticals' Earnings Yield (Joel Greenblatt) % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, SymBio Pharmaceuticals ranks #996 out of 1010 companies for Earnings Yield (Joel Greenblatt) %. This places SymBio Pharmaceuticals in the lower half of its industry. The industry median Earnings Yield (Joel Greenblatt) % is 2.97. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Drug Manufacturers company?
The median Earnings Yield (Joel Greenblatt) % among Drug Manufacturers companies is 2.97, based on 1,010 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on SymBio Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Earnings Yield (Joel Greenblatt) % is 2.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SymBio Pharmaceuticals's current Earnings Yield (Joel Greenblatt) % is -116.28%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SymBio Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, SymBio Pharmaceuticals (TSE:4582) is currently considered Fairly Valued. The stock's GF Value™ is 円52.24, compared to a current price of 円57.00 — trading 9.1% above its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is -116.28%. SymBio Pharmaceuticals' overall GF Score™ is 36/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For SymBio Pharmaceuticals (TSE:4582), the current Earnings Yield (Joel Greenblatt) % is -116.28% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SymBio Pharmaceuticals (TSE:4582) Overvalued in 2026?
Based on GuruFocus' analysis, SymBio Pharmaceuticals stock appears to be overvalued.
The current stock price of 円57.00 is trading 9.1% above its estimated GF Value™ of 円52.24.
GuruFocus considers SymBio Pharmaceuticals to be Fairly Valued.
Key valuation signals for TSE:4582:
Earnings Yield (Joel Greenblatt) %: -116.28%
GF Value™: 円52.24 vs. price of 円57.00 (9.1% above fair value)
No single metric tells the full story. See the TSE:4582 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SymBio Pharmaceuticals Ltd is a biopharmaceutical company engaged in development of new drugs with a primary focus on the treatment of rare diseases, mainly in the areas of oncology, hematology and multiple viral infections, and conduct integrated business activities that encompass search for new drug candidates, development, manufacturing, and sales.
36GF Score
Get the complete analysis for TSE:4582
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4582 has been successfully added to your 
